Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$322.83 +1.4%	$286.24	$205.87 ▼ $326.03	$42.09B	0.22	859,177 shs	2.05 million shs
GMAB Genmab A/S	$20.50 -1.1%	$20.98	$17.24 ▼ $28.56	$13.15B	0.96	1.22 million shs	727,649 shs
ROIV Roivant Sciences	$11.39 -1.8%	$11.11	$8.73 ▼ $13.06	$7.74B	1.16	5.64 million shs	11.13 million shs
TEVA Teva Pharmaceutical Industries	$16.76 +1.2%	$16.72	$12.47 ▼ $22.80	$19.22B	0.6	10.29 million shs	8.94 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+4.24%	+10.22%	+20.25%	+31.68%
GMAB Genmab A/S	0.00%	-3.12%	-3.85%	+3.02%	-20.14%
ROIV Roivant Sciences	0.00%	-0.52%	+0.80%	+9.73%	+7.76%
TEVA Teva Pharmaceutical Industries	0.00%	-1.25%	-4.71%	+11.29%	+3.11%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.1665 of 5 stars	2.4	4.0	4.3	3.3	2.5	0.6
GMAB Genmab A/S	4.0942 of 5 stars	3.3	5.0	0.0	3.4	0.0	3.1
ROIV Roivant Sciences	2.0279 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.0
TEVA Teva Pharmaceutical Industries	4.005 of 5 stars	4.6	3.0	0.0	1.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.79	Moderate Buy	$337.91	4.67% Upside
GMAB Genmab A/S	2.67	Moderate Buy	$37.60	83.41% Upside
ROIV Roivant Sciences	3.00	Buy	$17.50	53.64% Upside
TEVA Teva Pharmaceutical Industries	3.22	Buy	$24.13	43.99% Upside

Current Analyst Ratings Breakdown

Latest ROIV, ALNY, TEVA, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/12/2025	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $338.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
5/28/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.72	N/A	N/A	$0.52 per share	620.83
GMAB Genmab A/S	$3.12B	4.21	$1.52 per share	13.52	$8.04 per share	2.55
ROIV Roivant Sciences	$29.05M	266.54	N/A	N/A	$7.45 per share	1.53
TEVA Teva Pharmaceutical Industries	$16.54B	1.16	$3.36 per share	4.98	$4.74 per share	3.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	362.73	N/A	-11.49%	-510.31%	-6.48%	7/30/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.76	11.65	11.52	6.76	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.37	0.86	-7.74%	45.44%	6.95%	7/30/2025 (Estimated)

Latest ROIV, ALNY, TEVA, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
GMAB Genmab A/S	N/A	5.34	5.32
ROIV Roivant Sciences	N/A	33.47	33.47
TEVA Teva Pharmaceutical Industries	2.59	1.03	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
GMAB Genmab A/S	7.07%
ROIV Roivant Sciences	64.76%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
GMAB Genmab A/S	1.54%
ROIV Roivant Sciences	7.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
GMAB Genmab A/S	2,682	641.22 million	631.35 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

ROIV, ALNY, TEVA, and GMAB Headlines

Recent News About These Companies

Achmea Investment Management B.V. Sells 122,509 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 28 at 5:26 AM | marketbeat.com

UBS Group Lowers Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $23.00

June 28 at 2:33 AM | americanbankingnews.com

Teva’s CEO shares ‘Pivot to Growth’ progress

June 27 at 6:41 PM | fiercepharma.comF

Zacks Research Has Optimistic Outlook of TEVA Q1 Earnings

June 27 at 6:39 AM | marketbeat.com

Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

June 27 at 4:54 AM | ophthalmologytimes.comO

Teva Releases Q2 2025 Aide Memoire

June 26 at 4:45 PM | financialpost.comF

Teva Releases Q2 2025 Aide Memoire

June 26 at 4:30 PM | globenewswire.com

Teva Pharmaceutical Industries (NYSE:TEVA) Given New $23.00 Price Target at UBS Group

June 26 at 10:32 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by GHP Investment Advisors Inc.

June 26 at 4:17 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd (TEVA) Announces Upcoming Q2 2025 Financial Results Release ...

June 25, 2025 | gurufocus.com

Teva points to long-term efficacy of Ajovy in migraine

June 25, 2025 | thepharmaletter.comT

Teva Pharmaceutical Industries Ltd. to Announce Second Quarter 2025 Financial Results on July 30, 2025

June 25, 2025 | quiverquant.comQ

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025 | financialpost.comF

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025 | globenewswire.com

Teva Pharmaceutical Industries Ltd. - Page 2 - The New York Times

June 25, 2025 | nytimes.com

Retirement Systems of Alabama Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 25, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd: Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic ...

June 24, 2025 | finanznachrichten.de

Teva Pharmaceutical Industries Presents Final Analysis of PEARL Study Demonstrating Sustained Effectiveness of AJOVY in Migraine Prevention at EAN 2025 Congress - Nasdaq

June 24, 2025 | nasdaq.com

TEVA Teva Pharmaceutical Industries Limited - Seeking Alpha

June 24, 2025 | seekingalpha.com

Teva reports final analysis of migraine prevention trial of Ajovy

June 24, 2025 | msn.com

Whalen Wealth Management Inc. Takes Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV, ALNY, TEVA, and GMAB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$322.83 +4.58 (+1.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$319.71 -3.12 (-0.97%)

As of 06/27/2025 05:59 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Genmab A/S NASDAQ:GMAB

$20.50 -0.23 (-1.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$21.34 +0.84 (+4.12%)

As of 06/27/2025 05:12 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Roivant Sciences NASDAQ:ROIV

$11.39 -0.21 (-1.81%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.34 -0.05 (-0.44%)

As of 06/27/2025 07:21 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Teva Pharmaceutical Industries NYSE:TEVA

$16.76 +0.20 (+1.18%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$16.65 -0.10 (-0.60%)

As of 06/27/2025 08:00 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time